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Drug Trials in Children: Ethical,
Legal, and Practical Issues
Ralph E. Kauffman, MD
I nvolvement of children in clinical trials of dnugs
entails issues and considerations that are unique to
children. This discussion focuses on selected ethical
issues of particular importance when engaging in
clinical trials in children, briefly reviews some legal
considerations, and concludes by discussing certain




General societal concern regarding the ethics of hu-
man experimentation is a recent phenomenon. Be-
fore World Wan II, clinical trials in general, and clini-
cal trials in children, were conducted in a rather in-
formal manner with little public scrutiny. Edward
Jennen first tested his smallpox vaccines on his first-
born son and on neighbors’ children. Caroline of En-
gland arranged for Jenner’s vaccine to be tested in
children from a foundling hospital before it was ad-
ministered to the royal children. When Joseph Meis-
ten contracted rabies and was brought to Louis Pas-
teur, Pasteur consulted with two medical colleagues
and then intervened at the point that everyone
agreed “the death of the child appeared inevitable.”
The Nurembeng trial of Nazi doctors resulted in a
code of ethics fon human experimentation. However,
the Nuremberg code1 did not specifically address re-
search in children and received little attention be-
fore the late 1960s.
In 1964, the need for special protection and surro-
gate decision making for subjects with limited capac-
ity to consent was recognized in the World Medical
Association’s Declaration of Helsinki.2
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Dr. Henry Beecher published a paper in the New
England Journal of Medicine in 1966 on Ethics and
Clinical Research in which he censured 22 human
studies published in prestigious U.S. journals for vio-
lating basic ethical principles of human neseanch.
One of the objects of Beecher’s criticism was a study
of viral hepatitis, published in the NEJM (1958), per-
formed at Willowbnook State School in which 51
mentally retarded children were purposefully fed
infectious fecal extracts to study viral hepatitis.
Beechen’s paper was followed by an outcry from mul-
tiple facets of society alleging unethical practices and
violations of individual human nights during the
conduct of medical research. This culminated in
1974 in the establishment of the National Commis-
sion for the Protection of Human Subjects of Biomedi-
cal and Behavioral Research. The report of the Na-
tional Commission was published in 1978.
Concurrently with the National Commission’s
work, the Committee On Drugs of the American
Academy of Pediatrics, under contract with the
FDA, developed guidelines for the ethical study of
drugs in infants and children which were published
in 1977.6 The COD guidelines recently have been re-
vised and will be published in late 1993 or early
1994. Both the HHS and AAP documents have had a
profound impact on conduct of drug studies in chil-
dren during the past decade.
Ethical Considerations When Doing Studies
in Children
The regulations and guidelines for the protection of
all human subjects anise from three basic premises:
I.Respect for the rights of the individual;
2. The obligation to protect the individual from un-
due risk; and
3. Fairness in distribution of the burdens and bene-
fits of research.
Children comprise a particularly vulnerable popu-
lation that must be afforded protections over and
above those provided to autonomous adults because
of their limited cognitive abilities compared with
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normal adults and their dependency on responsible
adults. Several areas are of particular importance to
children.
Informed Consent. The principle of respect for the
rights of the individual demands that the individual
not be a research subject without being informed
about the benefits and risks of the research and freely
giving permission to participate as a research sub-
ject. However, children are not recognized under
law as autonomous individuals, although they do
enjoy individual rights. In addition, they do not pos-
sess the intellectual maturity to independently con-
sent to participate as research subjects. Therefore,
consent must be given by a surrogate, e.g. a responsi-
ble adult who usually is the parent. In doing so, it is
assumed that the surrogate is acting in the best inter-
ests of the child and is not influenced by factors that
may not be in the child’s interest. Investigators need
to be sensitive to situations in which the legal surro-
gate consenton may not be acting solely in the best
interests of the child.
To the extent they are capable, children should be
allowed to participate in the consent decision along
with the surrogate consenton. Consent of children
>13 years should be obtained unless there is an
overriding reason why this should not be done. Also,
children >7 years of age should have the right to say
“no” to participation, unless doing so would clearly
not be in their best interest. The Academy of Pediat-
rics Statement has referred to this as “assent.”
Risk/Benefit. Considerations of risk assume that the
study is well designed and has scientific merit. Partic-
ipation in poorly designed or scientifically nonmeri-
torious studies can never be defended as ethical re-
gardless of how little risk is involved.
In most instances the risk to child subjects is re-
duced by commencing studies in children after ani-
mals and initial studies in adults have documented
acceptable safety. In some cases this is not possible;
for example when the treated condition only occurs
in children and/on the drug is too toxic to study in
adult volunteers.
Because of their particular vulnerability and in-
ability to independently consent to participate as re-
search subjects, children are provided extra protec-
tion against undue risks. Both the Federal and Acad-
emy of Pediatrics guidelines have defined risk in
terms of minimal risk and greater than minimal risk.
Risk is relative and must always be defined in rela-
tion to possible benefits from participation. Some
risk factors that deserve special attention for chil-
dren are fear of a procedure, pain, and separation
from panents or familiar surroundings.
Children should be permitted to participate in
studies involving minimal risk if the study promises
benefit to the larger society of children, to a specific
group of children, and/on to the individual child.
With rare exception, participation in research in-
volving greater than minimal risk should be re-
stricted to studies presenting the prospect of direct
benefit to the individual subject. In this case, the re-
lationship of the anticipated benefit to the risk
should be at least as favorable as that presented by
available alternative therapies. Typically such stud-
ies are carried out in a therapeutic context, e.g., the
child is participating in a study as a part of their medi-
cal care.
Selection of Subjects. No particular socioeconomic,
racial, or ethnic group within largen society should
participate disproportionately in a clinical trial un-
less the selection is a necessary part of the study (i.e.,
study of cystic fibrosis, European Americans or
sickle-cell anemia, African Americans). Likewise, no
particular group should be excluded from the bene-
fits of a clinical trial unless the exclusion is dictated
by the inherent characteristics of the population
and/or the purpose of the study.
A related issue is compensation for participation.
While reimbursement for direct expenses, time, and
inconvenience associated with participation may be
appropriate, compensation which results in unfair
inducement to participate by a particular segment of
the population should be avoided. In addition, it is
important to avoid incentives sufficient to induce
surrogates to consent for a dependent to participate
in a study or subject them to painful or invasive pro-
cedures.
Special Populations. Certain populations of children
deserve special mention because they are more vul-
nerable than the general population of children and
therefore must be afforded special protection.
Institutionalized children, both handicapped and
non-handicapped, are at increased risk for exploita-
tion. Furthermore, surrogate consent presents spe-
cial problems in this population. Therefore, these
children should not be included in clinical trials un-
less they directly benefit from participation and/or
the subject of the trial pertains to their special cir-
cumstance of being institutionalized. On the other
hand, such children should not be excluded from
therapeutic trials from which they could directly
benefit. Additional protection may be provided by an
advocate who is independent of the investigator, in-
stitution, and legal guardian.
Emancipated minors comprise another special pop-
ulation. In many states emancipated minors are le-
gally qualified to independently give consent for
medical treatment for themselves. It follows that
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they may be qualified to give independent consent to
participate in studies pertaining to the medical con-
dition for which they can legally give consent for
treatment. This is a delicate issue and the investiga-
tor is advised to rely heavily on critical review and
supervision by the responsibl’ IRB if this is done.
Children with permanently debilitating or lethal
diseases are uniquely dependent and vulnerable.
Children with malignancies and children with HIV
infection illustrate this dilemma. In some cases po-
tentially efficacious drugs can only be studied in this
population. Many of the investigational protocols re-
sult in substantial morbidity and suffering. Can one
always assume the surrogate consentor is making the
best decision for the child? At what point does the
child have a right to refuse to participate?
HIV infection poses additional problems because
of the stigmata attached to it by society. How does
one maintain anonymity for the child and parents?
Because HIV infection is predominantly associated
with high-risk lifestyles, how does this affect the abil-
ity of the parent to act as a responsible surrogate for
the child?
Investigation involving these special groups re-
quires particular diligence on the part of the investi-
gator and IRB to be sure the child is adequately pro-
tected and at the same time has access to the benefits
of available research studies.
LEGAL ISSUES
Legal considerations impinge on drug trials in chil-
dren at several levels. These include pertinent Fed-
eral regulations, labeling requirements, and civil lia-
bility.
Federal Regulations
Investigators and sponsors of clinical trials must, of
course, be in compliance with applicable federal stat-
utes and regulations that govern research in human
subjects. Among other things, HHS regulations re-
quire that studies to be conducted in human subjects
be reviewed and approved by an Institutional Re-
view Board. This is one of the ways society has for-
malized its obligation to protect the rights and wel-
fare of the human subject. The regulations also re-
quire that informed consent be obtained before
participation. In the case of the dependent child, sur-
rogate consent must be obtained, usually from the
parent or legal guardian. Criminal law may also
speak to the issue of consent. In many jurisdictions,
the physician may be committing battery if any
treatment or procedure is administered without con-
sent.
The FDA has never implemented regulations spe-
cifically governing testing of drugs in children, al-
though guidelines do exist. They have relied on the
HHS regulations and reviewed pediatric issues on a
case by case basis.
Civil Liability
There seems to be widespread concern on the part of
industry sponsors that clinical trials in children are
associated with substantially greaten liability risk
than trials involving adults. However, litigation as a
direct result of injury associated with clinical trials
has been rare. Likewise, civil suits against clinical
investigators have been rare. This appears to be
somewhat uncharted territory with few legal prece-
dents. However, to date, the fear of civil liability
suits appears to be more real than the reality of ac-
tual suits. Although liability suits may not have sig-
nificantly influenced the conduct of pediatric clini-
cal trials, the concern about liability has been a de-
terrent to doing trials in children. Mr. Brian Yolles,
an attorney speaking at the IOM workshop on Drug
Development and the Pediatric Population, held
April 23-24, 1990, pointed out that if HHS regula-
tions or FDA or COD guidelines are not followed,
there is potential for liability. IRBs also may share
liability if guidelines are not followed. However,
even if guidelines are followed there is still potential
liability if courts and juries view the guidelines as
the minimal standard.
On the brighter side, Mr. Yolles predicted that
courts will be reluctant to impose liability on spon-
sors of well-controlled trials of drugs in children. He
pointed out that testing of drugs has become recog-
nized by society and by the courts as increasingly
important. If drugs are to be used safely and effec-
tively in children, they must be tested in children.
IRBs also are not immune to civil complaints on
the basis of their approval on disapproval of study
protocols. In 1973 the University of California was
sued to revoke approval by their IRB of a 5-year al-
lergy study which included normal children as con-
trols.7 The suit was filed by a dissenting member of
the IRB who alleged that normal children were being
volunteered for invasive procedures as part of the
study and payment to parents of $300 constituted
undue inducement to persons in economic distress.
Labeling Requirements for Children
Drugs cannot be labeled for use in children unless
the statutory requirements for evidence of safety and
efficacy are met. This requires that well-controlled
trials be conducted in the age groups for which the
drug is labeled. Because of lack of such trials and/or
absence of such data in the New Drug Application,
the majority of drugs on the market are not labeled
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for use in children. This places the physician caring
for children in the untenable position of not pre-
scribing many medications for children or prescrib-
ing off label. Frequently the latter is a necessary
choice. When prescribing off label, it is important to
recognize that FDA-approved labeling regulates the
drug in interstate commerce, not medical practice.
However, off label prescribing places an increased
burden of proof on the physician to establish the sci-
entific and medical basis for doing so. In this sense, it
may increase the physician’s liability potential. The
physician may actually Be in a stronger position with
respect to liability when administering a medication
off label under an approved protocol than when do-
ing so as a routine prescription.
PRACTICAL ISSUES
The essential ingredients for successful clinical trials
are: 1) investigator expertise; 2) clinical and techni-
cal facilities; 3) adequate patient population; and 4)
funding.
Ethical considerations and technical constraints
are frequently cited as impediments to pediatric stud-
ies. However, they contribute minimally to lack of
pediatric research. An ethical framework within
which to do pediatric studies has been in existence
since 1977 and advances in technology have negated
technical constraints as a rate-limiting factor. Al-
though regulatory constraints have been a reality,
the FDA has taken steps to address this issue. There-
fore, ethical, technical, or regulatory issues are not
major impediments to conducting clinical trials in
children.
Patient Population
With rare exception, drug studies in children require
access to a population of ill children for which the
drug holds some promise of benefit. Availability of
an appropriate patient population is most commonly
the rate limiting step in successfully conducting stud-
ies in children. Optimal patient populations are most
easily identified in large pediatric facilities. Some
disease entities are rare enough that no center can
enroll enough patients for a meaningful study within
a reasonable time period. On the other hand, certain
clinical trials may best be carried out in large ambu-
latory pediatric practices.
Funding
Clinical trials in infants and children tend to be more
expensive than comparable trials in adults. Several
factors contribute to this. For example, pediatric
studies pose logistic challenges that require greater
personnel time and effort than adult studies. Further-
more, pediatric studies frequently are, of necessity,
opportunistic. This tends to prolong enrollment time
and increase cost.
Although pediatric studies may be more expen-
sive, the incentive to fund pediatric studies is less. In
the case of most pharmaceutical products, the pediat-
ric share of the market is a small fraction of the total
market. Because of this, along with liability con-
cerns, there is limited economic incentive to invest a
great deal in clinical studies in children. This has
resulted in a majority of drugs entering the market
place and finding their way into off label use in chil-
dren with little or no data in children. The economic
impediments to pediatric drug studies need to be re-
duced. Several recent initiatives promise to help ad-
dress this issue. The FDA has proposed regulatory
changes to facilitate inclusion of pediatric indica-
tions in labeling for new drugs, the NIH will be fund-
ing a pediatric clinical trials network, and proposed
legislation is under review which would extend the
period of exclusivity (patent protection) of new drugs
for which clinical trials are done to support pediatric
labeling.
SUMMARY
Technical limitations, logistic challenges, and ethi-
cal constraints no longer provide excuses for not
conducting well-designed studies of therapeutic
agents in children. In fact, to not do so is difficult to
defend ethically. Clinical trials in children are feasi-
ble and essential for safe and effective use of medica-
tions in children. The time is long past when drugs
with therapeutic potential in children should be
marketed with labeling for use only in adults.
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